Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).
Relapsed/Refractory Multiple Myeloma
BIOLOGICAL: UCARTCS1A
Safety of UCARTCS1A, Incidence, nature and severity of adverse events and serious adverse events (SAEs) throughout the study., 24 months.
Response Assessment, At Day 35, Day 56 (M2), Day 84 (M3), Follow-up \[Q3M up to Month 24; i.e., Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21 and Month 24, 24 months|Duration of Response, Time Frame: From the date of the initial response to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24\], 24 months|Progression Free Survival, From the first day of study treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24, 24 months|Overall Survival, From the first day of study treatment to the date of death from any cause, assessed up to Month 24, 24 months
This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).